Health Information Center

Pfizer’s novel NGF pain drug is potential game changer

Phase II clinical trials of tanezumab in osteoarthritis, chronic low back pain and interstitial cystitis have demonstrated the drug’s analgesic efficacy across these three chronic pain settings. Despite safety concerns and a high price point, it expects tanezumab to enjoy a significant first-in-class advantage in a potentially lucrative novel area of pain therapy. ( http://www.bharatbook.com/detail.asp?id=130154&rt=Stakeholder-Insight-Osteoarthritis-Drug-development-lags-behind-rising-osteoarthritis-population.html )

Pfizer has announced positive results from three Phase II trials in pain at the American Academy of Pain Medicine’s 26th Annual Meeting. The randomized, double-blind, placebo-controlled six-week trials in patients with chronic low back pain (CLBP) and interstitial cystitis receiving a single intravenous infusion of tanezumab (200mcg/kg) met their primary endpoints of significantly superior pain relief over placebo. Continue reading ‘Pfizer's novel NGF pain drug is potential game changer’ »

Oncology Market Leaders – Analyses and Outlook – 2010-2025

Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). Furthermore, anti-cancer drug sales exceeded $50bn worldwide in 2009. The oncology drug market has grown impressively, driven by rising disease prevalence, expanding patient populations and technological advances, especially in biomolecular medicine. Current treatments are better-tolerated, more- effective and more-commercially-successful than ever before, our latest report shows. ( http://www.bharatbook.com/detail.asp?id=132312&rt=Oncology-Market-Leaders-Analyses-and-Outlook-2010-2025.html )

The aging of populations, lifestyle changes in the developing world, together with significant advances in pharmacotherapy and diagnostics, will drive the cancer treatments market from 2010 onwards. Increasing disease prevalence and a strong R&D pipeline make the anti-cancer sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report, Oncology Market Leaders – Analyses and Outlook – 2010-2025, explains why and to what extent, revealing where the most-exciting and lucrative developments will lie from 2010 onwards. There, you will find detailed sales predictions and supporting discussions. Continue reading ‘Comprehensive Analysis Of The Oncology Market Sector’ »

EASD 2009: Lantus defended amid allegations of increased cancer risk

It presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed. ( http://www.bharatbook.com/detail.asp?id=91847&rt=Commercial-Insight-Cardiovascular-and-Metabolic-Market-Overview-Diabetes-to-the-fore-as-generics-hit-primary-care-markets.html )

Although the European Association for the Study of Diabetes (EASD) recommended the continued use of Lantus in type 1 and type 2 diabetics, it has called for increased research into the relationship between insulin therapy – particularly Lantus (insulin glargine; Sanofi-Aventis) – and the risk of cancer.

It was postulated during the discussion at the 2009 EASD meeting that insulin use may be related to the increased incidence of cancer seen in diabetics over that seen in the general population. The preliminary data discussed in the symposium suggested lower rates of cancer with Levemir (insulin detemir; Novo Nordisk) compared to neutral protamine Hagedorn (NPH), but higher rates with Lantus. Continue reading ‘EASD 2009 – Lantus defended amid allegations of increased cancer risk’ »

Axcan Pharma Inc.-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies.

Scope of the reports

Accessing accurate, current and comprehensive content on private companies can be challenging and Life Science Analytics has created a suite of reports that deliver the latest information on over 1,000 private firms. Each report provides a corporate overview and business description along with detail on the company’s management team and its products. . Continue reading ‘Axcan Pharma Inc.-Company Report’ »

Cancer Head and Neck Cancer Therapy Area Pipeline Report

This report contains detailed information on the head and neck cancer drug pipeline. This report provides insight into the pipeline status of head and neck cancer drugs by company and by stage as well as a summary of the latest news and developments in this area. ( http://www.bharatbook.com/detail.asp?id=126756&rt=Cancer-Head-and-Neck-Cancer-Therapy-Area-Pipeline-Report.html )

Scope of the report:

Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area. Continue reading ‘Cancer Head And Neck Cancer Therapy Area Pipeline Report’ »

Alliance Pharma plc-Company Report

Bharatbook.com added a new report on “Alliance Pharma plc-Company Report” into its market report catalogue for reselling.

Alliance Pharma plc-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies.

Scope of the reports

Accessing accurate, current and comprehensive content on private companies can be challenging and Life Science Analytics has created a suite of reports that deliver the latest information on over 1,000 private firms. Each report provides a corporate overview and business description along with detail on the company’s management team and its products. . Continue reading ‘Alliance Pharma plc-Company Report’ »

Preclinical Models: Innovative solutions to accelerate drug discovery and development

Preclinical models are developed to test lead compounds for toxicity and efficacy. They are valuable tools to minimize development costs and reduce failures prior to commencement of human trials. Problems with traditional animal models such as cost, ethics, and suitability has prompted researchers to develop new models and systems to overcome such disadvantages. Continue reading ‘Preclinical Models – Innovative Solutions To Accelerate Drug Discovery And Development’ »

Oncothyreon, Inc.-Therapeutic Competitors includes a business summary, tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of development, and competitors by therapeutic indication. The report also includes recent company news updates.

Competitor Reports provide detailed analysis of a company’s products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted likelihood of clinical success for each pipeline product. Every Competitor Report compares the company against its primary competitors by individual therapeutic indication. Continue reading ‘Oncothyreon, Inc.-Therapeutic Competitors’ »

Opticians & Optical Goods – Market Assessment

This Market Assessment report provides an analysis of the opticians and optical goods market, which includes spectacles, contact lenses and solutions, laser eye treatment, sight tests and general ophthalmic services. It updates a previous Opticians & Optical Goods Market Assessment report published in August 2008. ( http://www.bharatbook.com/detail.asp?id=83563&rt=Opticians-Optical-Goods-Market-Assessment.html )

The market suffered the impacts of the recession in 2009 and several sectors experienced falling revenues. The downturn was the first reversal in an upward sales trend that had lasted for some years. Expenditure by opticians and suppliers of optical goods in areas such as main media advertising also declined in 2009, compared with 2008, and this was probably due in part to the recession. However, a growing population — in particular, the number of adults aged 60 and over — meant that the number of NHS sight tests taken in the year to March 2009 increased over the corresponding period of 2007/2008 and helped to sustain income from this source of revenue. Continue reading ‘Opticians & Optical Goods – Market Assessment’ »

Pipeline Insight: Leukemias Underserved patient populations offer potential for market growth

Despite major advances in treatment in the last decade, a considerable percentage of the leukemia population still has high unmet needs. Some key oncology companies have entered the leukemias market fairly recently while others are pursuing late-phase development in this indication, hoping to exploit the commercial potential of patient subgroups underserved by existing treatment options. ( http://www.bharatbook.com/detail.asp?id=134190&rt=Pipeline-Insight-Leukemias-Underserved-patient-populations-offer-potential-for-market-growth.html ) Continue reading ‘Pipeline Insight Leukemias Underserved Patient Populations Offer Potential For Market Growth’ »